Gilead says arthritis drug filgotinib fails in follow-up use trialsAs Gilead and Galapagos prepare their JAK inhibitor filgotinib for a US filing in rheumatoid arthritis, the drug Share XGilead says arthritis drug filgotinib fails in follow-up use trialshttps://pharmaphorum.com/news/gilead-says-arthritis-drug-filgotinib-fails-in-follow-up-use-trials/
Expect more M&A as Gilead names Dickinson as finance chief, say analystsGilead Sciences has named head of corporate development and strategy Andrew Dickinson as its new chief financial officer Share XExpect more M&A as Gilead names Dickinson as finance chief, say analystshttps://pharmaphorum.com/news/expect-more-ma-as-gilead-names-dickinson-as-finance-chief-say-analysts/
Humira tops list of drugs with unwarranted US price hikesAbbVie’s Humira heads a list of seven medicines that collectively contributed to a $5.1 billion increase in US Share XHumira tops list of drugs with unwarranted US price hikeshttps://pharmaphorum.com/news/humira-tops-list-of-drugs-with-unwarranted-us-price-hikes/
Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomaThe Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few Share XScotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomahttps://pharmaphorum.com/news/scotland-says-yes-to-gileads-car-t-yescarta-for-lymphoma/
Gilead will challenge US government patent on PrEP drug TruvadaGilead Sciences has said it plans to challenge patents held by the US government on the use of Share XGilead will challenge US government patent on PrEP drug Truvadahttps://pharmaphorum.com/news/gilead-will-challenge-us-government-patent-on-prep-drug-truvada/
Gilead’s Descovy gets FDA panel OK for PrEP, but not for womenGilead’s Descovy got a green light from an FDA advisory committee for HIV pre-exposure prophylaxis (PrEP) yesterday – Share XGilead’s Descovy gets FDA panel OK for PrEP, but not for womenhttps://pharmaphorum.com/news/gileads-descovy-gets-fda-panel-ok-for-prep-but-not-for-women/
FDA reviewer backs Gilead’s Descovy for PrEP, but not in womenGilead Sciences’ Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, is heading into an FDA advisory Share XFDA reviewer backs Gilead’s Descovy for PrEP, but not in womenhttps://pharmaphorum.com/news/fda-reviewer-backs-gileads-descovy-for-prep-but-not-in-women/
Gilead joins protein degradation drive with Nurix dealGilead has teamed up with protein degradation specialist Nurix on a project to find new cancer drugs, paying Share XGilead joins protein degradation drive with Nurix dealhttps://pharmaphorum.com/news/gilead-joins-protein-degradation-drive-with-nurix-deal/
